Search jobs 11-May-2021 Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
Collaboration aims to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disorders
Capsigen’s screening technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline
Capsigen to receive a $15 million upfront payment and is eligible to receive potential research, development and commercial milestone payments
Biogen Inc. (Nasdaq: BIIB) and Capsigen Inc. announced today that they have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to deliver transformative gene therapies that address the underlying genetic causes of various CNS and neuromuscular
Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration
May 11, 2021
Share
Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen.
The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed to combine Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform and associated technologies with Biogen’s discovery, development, manufacturing, and commercialization capabilities.
Capsigen’s technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline.
Biogen and Capsigen to collaborate on gene therapies
Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets
Biogen has announced a new strategic research collaboration with Capsigen to develop novel adeno-associated virus (AAV) capsids that have the potential to deliver gene therapies for CNS and neuromuscular disorders.
Under the terms of the agreement, Biogen will gain an exclusive right under Capsigen’s proprietary technology for an undisclosed number of CNS and neuromuscular disease targets.
Biogen will pay Capsigen a $15m upfront payment as well as up to $42m in potential research milestones and up to an additional $1.25bn in potential development and commercial payments.